{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T21:08:54Z","timestamp":1772312934052,"version":"3.50.1"},"reference-count":19,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2018,1,31]],"date-time":"2018-01-31T00:00:00Z","timestamp":1517356800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2018,3]]},"abstract":"Abstract<\/jats:title>Several chemotherapy regimens have been developed for the treatment of acute lymphoblastic leukemia (ALL<\/jats:styled-content>), but relapse still presents the most common obstacles to attaining long\u2010term survival. The hyper\u2010CVAD<\/jats:styled-content> (hyperfractionated cyclophosphamide, vincristine, doxorubicin, and prednisolone)\/HD MTX<\/jats:styled-content> and Ara\u2010C (high\u2010dose methotrexate and cytarabine) chemotherapy regimen was first started in the MD<\/jats:styled-content> Anderson Cancer Center as an intensive regimen for adult patients with ALL<\/jats:styled-content>. The purpose of this study was to evaluate the effectiveness of a modified hyper\u2010CVAD<\/jats:styled-content> protocol. We used hyper\u2010CVAD<\/jats:styled-content> as consolidation\/maintenance after remission induction with daunorubicin, vincristine, and prednisolone (and cyclophosphamide for T\u2010cell ALL<\/jats:styled-content> only) rather than standard hyper\u2010CVAD<\/jats:styled-content> in order to reduce treatment complications. This study was conducted as a retrospective review of medical records of ALL<\/jats:styled-content> patients at 501 army hospital, Tehran, Iran, from 2005 to 2015. Three hundred and one patients underwent modified hyper\u2010CVAD<\/jats:styled-content> chemotherapy regimen. Complete remission and overall survival (OS<\/jats:styled-content>) rates were measured as primary endpoints. Two hundred and forty\u2010six (81.7%) reached complete remission (CR<\/jats:styled-content>) during the first 6\u00a0months of treatment, and 55 patients (18.3%) did not reach CR<\/jats:styled-content>. The 5\u2010year OS<\/jats:styled-content> rate was 51.8% (95% CI<\/jats:styled-content> (confidence interval): 45.1\u201357.8%). Modified hyper\u2010CVAD<\/jats:styled-content> regimen is an efficient intensive chemotherapy regimen for consolidation\/maintenance of adults with newly diagnosed ALL<\/jats:styled-content> and has an acceptable 5\u2010year overall that is comparable to standard hyper\u2010CVAD<\/jats:styled-content> regimen.<\/jats:p>","DOI":"10.1002\/cam4.1328","type":"journal-article","created":{"date-parts":[[2018,1,31]],"date-time":"2018-01-31T05:02:48Z","timestamp":1517374968000},"page":"594-599","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Effectiveness of modified hyper\u2010CVAD<\/scp> chemotherapy regimen in the treatment of adult acute lymphoblastic leukemia: a retrospective experience"],"prefix":"10.1002","volume":"7","author":[{"given":"Hasan","family":"Jalaeikhoo","sequence":"first","affiliation":[{"name":"AJA Cancer Epidemiology Research and Treatment Center (AJA\u2010 CERTC) AJA University of Medical Sciences Tehran Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohsen","family":"Rajaeinejad","sequence":"additional","affiliation":[{"name":"AJA Cancer Epidemiology Research and Treatment Center (AJA\u2010 CERTC) AJA University of Medical Sciences Tehran Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manoutchehr","family":"Keyhani","sequence":"additional","affiliation":[{"name":"Hematology and Oncology Research Center Vali\u2010Asr Hospital Tehran University of Medical Sciences Tehran Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Zokaasadi","sequence":"additional","affiliation":[{"name":"AJA Cancer Epidemiology Research and Treatment Center (AJA\u2010 CERTC) AJA University of Medical Sciences Tehran Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9982-2917","authenticated-orcid":false,"given":"Mohammad Mehdi","family":"Dehghani Firoozabadi","sequence":"additional","affiliation":[{"name":"AJA Cancer Epidemiology Research and Treatment Center (AJA\u2010 CERTC) AJA University of Medical Sciences Tehran Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,1,31]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V85.5.1151.bloodjournal8551151"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.6916"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V85.8.2025.bloodjournal8582025"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-01-130237"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-014-2258-y"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2014.03.004"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20668"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.3.547"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V122.21.5014.5014"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.53"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.3109\/0284186X.2014.889850"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.3310\/hta14540"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.4084\/mjhid.2014.065"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2013.122"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2006.1.142"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-03-082933"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198909213211203"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.2.464"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-116582"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcam4.1328","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.1328","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T16:47:27Z","timestamp":1747673247000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.1328"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,31]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["10.1002\/cam4.1328"],"URL":"https:\/\/doi.org\/10.1002\/cam4.1328","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,31]]},"assertion":[{"value":"2017-10-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-12-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-01-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}